Opening New Frontiers

Size: px
Start display at page:

Download "Opening New Frontiers"

Transcription

1 Opening New Frontiers Roadshow presentation 2Q11 results 1

2 2

3 AGENDA Solvay, an industrial group active in Chemistry Friendly offer on Rhodia 2Q11 results 3

4 SOLVAY GROUP SOLVAY at a glance SOLVAY AN INDUSTRIAL GROUP ACTIVE IN CHEMISTRY Clear leadership positions Diversified customer base Significant Asian & Latin American exposure Competitiveness Conservative financial structure Strong product innovation Towards sustainability 4

5 SOLVAY GROUP Clear leadership positions EUROPE WORLD Specialty Polymers Fluorinated polymers High performance engineering polymers Special Chemicals Niche player Niche player Essential Chemicals Soda ash Hydrogen peroxide Vinyls 2 3 5

6 SOLVAY GROUP Broadest portfolio of high and ultra high performance polymers PVDC PPA PARA PPS LCP PSU PESU PPSU PEEK PAI PI SRP/ HPS PEI PTFE PVDF FEP MFA PFA FKM/ FFKM PFPE ECTFE Solvay Arkema BASF Daikin DuPont Dyneon EMS Evonik Kuraray MEP SABIC Ticona Victrex 6

7 SOLVAY GROUP Leadership positions SODA ASH Nameplate capacities as of 1 Jan 2011 in million tons SHANDONG HAIHUA ORIENTAL CHEMICAL HYDROGEN PEROXIDE Nameplate capacities as of 1 Jan 2011 in thousand tons EKA FMC FMC TATA CHEMICALS +40% ARKEMA EVONIK +60% SOLVAY SOLVAY EUROPE + CIS NAFTA AFRICA ASIA-PACIFIC EUROPE NAFTA Latin America ASIA-PACIFIC AFRICA PVC Nameplate capacities as of 1 Jan 2011 in million tons CAUSTIC SODA Nameplate capacities as of 1 Jan 2011 in million tons INEOS VINYLS OXIVINYLS SOLVAY FORMOSA PLASTICS SHINETSU INEOS VINYLS OXIVINYLS SOLVAY FORMOSA PLASTICS SHINETSU EUROPE NAFTA Latin America ASIA-PACIFIC EUROPE NAFTA Latin America ASIA-PACIFIC AFRICA Source: Solvay, calculations based on information publicly available in external publications, in particular IMS, Harriman Chemsult, CMAI, SRI 7

8 SOLVAY GROUP Diversified customer base in % of 2010 sales (continuing operations, excluding Inergy Automotive Systems (= EUR 6.5 bn)) Contruction and architecture Chemical industry Paper & packaging Water and Environment Electrecity and Electronics Glass industry Detergents, cleaning and Hygiene products Consumer goods Automotive industry 13% 9% 7% 7% 6% 5% 4% 4% 23% of Group sales Vinyls, Specialty Polymers, Fluor of Group sales Electrochemistry, Soda Ash, Fluor of Group sales Vinyls, Hydrogen peroxide, Specialty Polymers of Group sales Pipelife, Soda ash, Specialty Polymers of Group sales Specialty Polymers, Vinyls of Group sales Soda ash of Group sales Soda Ash, Hydrogen peroxide, Electrochemistry of Group sales Vinyls, Specialty Polymers of Group sales Specialty Polymers 8

9 SOLVAY GROUP Worldwide diversified activities 2010 SALES BREAKDOWN BY REGION 59% 16% 14% 11% 2010 FIXED ASSETS BREAKDOWN BY REGION 55% 22% 11% 11% 9

10 SOLVAY GROUP Developments in emerging countries RUSSIA & EASTERN EUROPE RusVinyl ASIA Construction of a new production unit of vinyls (2013) China Construction of H 2 O 2 plant with Huatai Group (2011) RUSSIA & EASTERN EUROPE ASIA Construction of two Specialty Polymers plants (1H12 and 1H14) Project to construct Epicerol plant (2013) Agreement with Tianjin Soda Ash Plant to acquire 30% participation in a soda ash plant Thailand Construction of HPPO plant with Dow Chemicals (3Q11) Construction of Epicerol plant (2012) 10

11 SOLVAY GROUP Vertical integration in main raw materials PRODUCT HYDROGEN (H 2 O 2 ) 60 % coverage of our needs FLUORSPAR (FLUORINATED PROD.) 75% coverage of our needs SALT (PVC / NAOH / SODA ASH) 100% coverage of our needs (1) LIMESTONE / TRONA (SODA ASH) 100% coverage of our needs (1) this doesn t exclude opportunistic purchases 11

12 SOLVAY GROUP From raw materials to finished products LIMESTONE TRONA Soda ash Sodium bicarbonate Ethylene (partly integrated) SALT BRINE Caustic soda Chlorine Chlorinated derivatives : organic (epichlorhydrin) inorganic VCM PVC VDC PVDC Hydrogen peroxide Peracetic acid Persalts FLUOR SPAR Hydrogen peroxide Inorganic fluorides HFC Brazing, electronic,... Refrigerants, foam blowing agents,... PVDF PTFE PFA/MFA ECTFE FKM FFKM PFPE 12

13 SOLVAY GROUP Competitiveness example of PVC SOLVAY S CAPACITY PER SITE WELL ABOVE THE AVERAGE (1) Average capacity per site in 2010 in W.Europe +51% Average capacity per site in 2010 in SE Asia +107% SolVin Others Vinythai Others SIGNIFICANTLY LOWER FIXED COSTS Fixed cost/t of capacity of VCM/PVC evolution SolVin Indupa Vinythai (1) SOURCE: CMAI 13

14 SOLVAY GROUP Conservative financial structure NET CASH SURPLUS OF EUR 2.6BN AT THE END OF 2Q11 Gross financial debt: EUR 2.8bn Cash and cash equivalents: EUR 5.3bn NO SIGNIFICANT DEBT MATURITY DATES BEFORE 2014 (end of June 11) EMTN bonds Hybrid bonds Retails bonds Total gross debt 2.8 SOLVAY S FINANCIAL STRUCTURE AFTER RHODIA S ACQUISITION Should continue to be conservative Net financial debt of the combined entity 1 : EUR 1.9bn ~1x combined Net Debt / REBITDA End of 2010 pro forma figure 14

15 SOLVAY GROUP Shareholding structure and Board composition Total issued capital 84,701,133 shares Solvac (Founding families holding company listed on NYSE Euronext) : 30% Solvac (to cover share option program) : 3% Solvac (treasury share: 880,766 shares as of 28 July 2011) : 1% 16 Board Members Nationalities : 8 Belgian, 1 Dutch, 3 French, 1 German, 1 Spanish, 1 CH Executives : 2 (CEO & CFO), Chairman is previous CEO Independent Directors : 9 Some Directors are members of the founding families 15

16 NEW BUSINESS DEVELOPMENT Innovation in new and promising areas Organic Electronics Organic Light Emitting Diodes Organic Field Effect Transistors Organic Memories Nanotechnologies Electronics and IT Manufacturing and Materials Healthcare and life sciences Sustainable Energies Fuel cells Organic Photovoltaics (OPV) Hydrogen Storage New Batteries Renewable Based Materials and White Biotechnologies Renewable raw materials Process improvement using biotech New products 16

17 SOLVAY GROUP Towards sustainability Solvay is aiming to radically transform itself to bring more value to its customers, while reducing both its and their energy and environmental impact STRATEGIC MANAGEMENT REVIEW 2008 focused on Sustainable Development and our long-term vision SUSTAINABILITY REPORT with quantified targets PERFORMANCE INDICATORS 2010 quantified follow-up 17

18 18

19 AGENDA Solvay, an industrial group active in Chemistry Friendly offer on Rhodia 2Q11 results 19

20 SOLVAY-RHODIA Offer Highlights Rhodia s board unanimously supports the offer Cash Offer of EUR 31.6 per share of Rhodia 1 50% premium to pre-announcement closing price 44% premium to last 3 months average price Offer for equity linked OCEANE bonds Enterprise Value: EUR 6.6 bn Represents EV / REBITDA 2010 multiple of 7.3x 2 1 Ex-dividend of 0.5 EUR per share 2 VE / REBIDA 2010 = 8.5x Excluding CERs 20

21 SOLVAY-RHODIA Strategic rationale for the acquisition New growth and enlarged portfolio Increases scale with global leadership, 90% revenues made in segments with # 1, 2 or 3 positions Gears towards high growth markets and emerging regions Better balanced end markets and product complementarities Business and cultural fit Performance driven cultures with decentralized structures Core capabilities sharing Commitment to innovation with focus on sustainable development VALUE CREATION Enhanced financial profile REBITDA x 2 Cost synergies of EUR 250m over 3 years 21

22 SOLVAY-RHODIA Create a major global chemical player 1 From continuing operations SALES 2010, EUR bn REBITDA 2010, EUR bn Operating Cash Flow 2010, EUR bn 12,0 1,9 1,2 6,8 (1) 1,0 (1) 0,7 (1) Solvay Solvay & Rhodia Solvay Solvay & Rhodia Solvay Solvay & Rhodia 22

23 SOLVAY-RHODIA Strong leadership positions DIVERSIFIED PORTFOLIO WITH STRONG LEADING POSITIONS Segment Global market position Description Specialty Polymers #1 High-Performance Engineering Polymers, Fluorinated Polymers Polyamide Materials #2 PA 6.6 polymers, Intermediates & engineering plastics Consumer Chemicals #1 Specialty Surfactants, Phosphorus Chemistry, Diphenols for vanillin Advanced Materials #1 High-Performance Silicas, Rare Earths Systems Oxygen #1 Hydrogen Peroxide Minerals #1 Soda Ash, Sodium Bicarbonate #1, 2 global positions > 60 % of combined sales #1, 2, 3 global positions > 90% of combined sales 23

24 SOLVAY-RHODIA Strong footprint in developing regions 40% OF SALES FROM EMERGING MARKETS 1 Includes net sales and other revenues 2 Includes Eastern Europe NORTH AMERICA 17% WESTERN EUROPE 43% ASIA / PACIFIC REST OF THE WORLD (2) 25% LATIN AMERICA (1) 14% Solvay regional sales split Rhodia regional sales split % Sales combined Pro forma 24

25 SOLVAY-RHODIA Diversified end-markets portfolio Proforma 2010 Consumer goods Construction Automotive Energy, Water & Environment Electronics SOLVAY 4% 22% 9% 7% 7% RHODIA <40% >5% >20% 10% >5% COMBINED 19% 15% 14% 8% 6% 25

26 SOLVAY-RHODIA Innovation and technology focus to develop sustainable solutions for the future Solvay Developing low-carbon business opportunities: Specialty Polymers (e.g., light-weight and bio-based engineering polymers) EPICEROL to produce epichlorohydrin Innovation strongly focused on sustainability Fuel cell technology New generation of batteries Hydrogen storage Organic photovoltaic cells Rhodia Focus on sustainable products Advanced Materials (e.g. energy-saving light bulbs) Polyamide (e.g., light-weight plastics for automotive industry) Consumer Chemicals Energy Services (e.g. Carbon emission trading) Innovation aiming to further develop sustainability solutions (~90% of innovation) Recycling Recycling 26

27 SOLVAY-RHODIA Targeted synergies Cost synergies: EUR 250 m Targeted synergies: Based on good practices for business combinations 2/3 external 1/3 internal (mainly G&A) Achieved within 3 years Represents 2.1% of combined sales Represents 4.8% of Rhodia s sales (versus 4 to 9% cost synergies benchmark) Revenue synergies Driven by: Enlargement and globalization of customer base Benefiting across products from emerging markets platform 27

28 SOLVAY-RHODIA A solid financial performance to start from A EUR 12bn Chemicals Group REBITDA and REBIT x 2 Maintained conservative financial leverage (~1x combined Net Debt / REBITDA 2010) 2010 (EUR m) Solvay (1) + Rhodia = Combined Sales 6,796 5,226 12,022 REBITDA 1, ,924 REBITDA margin 15.0% 17.3% 16.0% REBIT ,204 REBIT margin 8.9% 11.5% 10.0% Operating Cash Flow ,165 Net Financial Debt (2.9) bn 1.2 bn 1.9 bn (2) Employees 16,800 14,100 30,900 (1) From continuing operations (2) Including 2010 dividend, transaction cost and fair value of debt 28

29 AGENDA Solvay, an industrial group active in Chemistry Friendly offer on Rhodia 2Q11 results 29

30 SOLVAY GROUP New organisation to foster sustainable growth Plastics Specialty Polymers : Global Business Unit Solvay's fluorinated polymers and high performance engineering polymers are used in a wide array of applications and markets, such as Electricity and Electronics, Water and Environment, Automotive and Consumer Goods Chemicals Special Chemicals : Global Business Unit Solvay's Special Chemicals such as high-purety fluorine, fluorinated gases, Barium, Strontium and wet chemicals are among others used for applications in Energy, Electronics, Agrochemicals, food & Feed, Healthcare & Performance Materials Vinyls : Regional Business Units Solvay's Vinyls are mainly used for Construction and Architecture, Water and Environment, Packaging and Consumer Goods Essential Chemicals : Regional Business Units Solvay's Essential Chemicals such as soda ash, bicarbonate, caustic soda and hydrogen peroxide are widely used in the Chemical and Glass industry and for applications in the fields of Water and Environment, Detergents, Cleaning and Hygiene products and Paper 30

31 SOLVAY GROUP Successful pricing power on strong demand SALES IN EURm 2Q11 1H Scope & Forex % 4% Price Volume Scope & Forex -37 7% Volume % Price Q10 2Q11 1H10 1H11 31

32 SOLVAY GROUP Excellent profitability REBITDA UP TO EUR 304m REBITDA MARGIN: Up to 18% in EURm % 17% 18% Q10 1Q11 2Q11 1H10 1Q11 2Q11 Chemicals Plastics CBS/NBD Group margin 32

33 2Q11 PLASTICS RESULTS REBITDA: EUR 197m, up by 22% REBITDA (EURm) and margins (%) REBITDA (EURm) and margins (%) Specialty Polymers 82 27% 10% 98 30% 15% Vinyls 65 11% 10% 99 15% 15% 2Q10 2Q11 2Q10 2Q11 RECORD REBITDA MARGIN Continued buoyant demand Increased margins thanks to better product mix, higher sales prices and operating excellence supporting high R&D pipeline REBITDA SHARPLY UP IN THE THREE REGIONS Favorable business dynamics: sustained demand in Asia, South America and recovering demand in Northern Europe Increased margins on ethylene and caustic soda 33

34 2Q11 CHEMICALS RESULTS REBITDA: EUR 127m, up by 6% REBITDA (EURm) and margins (%) REBITDA (EURm) and margins (%) Special Chemicals Essentials Chemicals % 16% 10% 16% 24 19% 18% 10% 15% 2Q10 2Q11 2Q10 2Q11 EXCELLENT REBITDA PERFORMANCE Excellent performance of fluorinated chemicals : higher volumes and sales prices compensate for increased costs Profitability of Molecular Solutions under review CONFIRMED RESILIENCE ACROSS CYCLES Strong demand; volumes up by 6%, mainly in soda ash with increased commercial presence in South America & Asia Successful pricing power: 10% higher sales prices compensating for rising energy costs 34

35 SOLVAY GROUP 26% of sales in emerging regions Group s sales breakdown by region 1H11 S.America EMEA: 60% North America: 14% ASIA South America: 11% EMEA Asia: 15% N.America 35

36 SOLVAY GROUP Net energy expenses Net energy expenses in % of sales 11.2% 12.7% 13.5% Initiatives in energy management Exeltium in France OPERATING Refuse Derived Fuel cogeneration plant at Bernburg OPERATING Conversion to membrane electrolysis Tavaux & Lillo

37 SOLVAY GROUP Other elements of the income statement In EURm 1H11 1H10 REBIT Non recurring items Financial charges Tax charges Result from continuing operations Result from discontinued operations Non-controlling interests Net income Solvay share

38 SOLVAY GROUP Cash management Strict industrial working capital management June 2011 vs June 2010 Industrial working capital +10% Sales +17% CAPEX focused on a limited number of strategic projects CAPEX in EURm 2009 BDG BDG 2011* 2009 BDG 2010 BDG2011* * calculated using equity method for Joint ventures Spent CAPEX (1H11) 38

39 PLASTICS Strategic developments PVC plant in Russia (2013) New Specialty Polymers plants in China (1H12 & 1H14) Specialty Polymers capacity extensions in Europe (2012) Electrolysis conversion membrane in Belgium (2012) 39

40 PLASTICS RusVinyl Financing Agreement signed in St Petersburg on June 17, 2011 State-of-the-art Vinyls plant in Russia Commissioning 2013 BUENOS AIRES 50/50 JV SolVin SIBUR Total investment: EUR 1.5 billion Debt financing: EUR 750m Sberbank of Russia (EUR 150m) EBRD (EUR 150m) BNP Paribas, ING Bank and HSBC (EUR 450m) Solvay investment share: EUR ~ 250m EBRD equity share: EUR 52m PVC Production capacity (kt/y) Average PVC plant in Russia 135 RusVinyl

41 CHEMICALS Strategic developments HPPO plant in Thailand (2H11) 30% share in a soda ash plant in China (2011) EPICEROL plant in Thailand (2012) Electrolysis conversion membrane in France (2012) 41

42 CHEMICALS New HPPO plant in Saudi Arabia Intention to form 50/50 JV with Sadara (50/50 Aramco and Dow) Hydrogen Peroxide for PO plant in Saudi Arabia BUENOS AIRES 3 rd megaplant and 3 rd region Commissioning 2H15 HPPO production capacity of Solvay will represent over 50% of its total H 2 O 2 capacity Current H 2 O 2 capacity H 2 O 2 capacity as from 2H15 HPPO: 45% HPPO: > 50% 1.2 million tons/year ~ 1.5 million tons/year

43 NEW BUSINESS DEVELOPMENT R&D and venture capital R&D commitment budgeted in 2011 EUR 145m R&D in the new business development EUR 35m Focus of New Business Development: Printable Organic Electronics Financing EUR 10m Plextronics polymer-based materials and technologies for printed electronics: such as OLED displays and lighting and organic photovoltaic cells (OPV) New and Renewable Energies Nanotechnologies Renewable Chemistry: renewable based materials & white biotechnologies Number of first new patent filings 1H11 vs 1H10 54 vs 34 43

44 SOLVAY GROUP Performance summary - HY 2011 STRONG SALES DEVELOPMENT SALES 3 388m EXCELLENT REBITDA PROFITABILITY 589m +17% +26% NET INCOME SHARPLY UP RESULT CONT. OP.* 274m SOUND CASH GENERATION OPERATING CASH FLOW 103m *From continuing operations 44

45 RHODIA Friendly cash offer for Rhodia CREATING A MAJOR GLOBAL CHEMICAL PLAYER Increases scale with global leadership 90% revenues made in segments with # 1, 2 or 3 positions Geared towards high growth markets and emerging regions Better balanced end markets and product complementarities Innovation and technology focus 45

46 RHODIA Indicative offer calendar Acquisition offer announced & filing Regulators approvals Closing & Settlement 2011 April May June July August September 04/04 Announcement of the offer 15/06 30/06 05/08 Opening of the offer Notification to the European Commission European Commission expected approval date 46

47 SOLVAY GROUP Outlook 2011 The Solvay Group is attentive to the macro-economic developments and the evolution of energy and ethylene costs. In the context of the current business climate and based on its strategy of sustainable and profitable growth, Solvay expects to improve its annual operating result, both in Chemicals and Plastics activities in Press release of July 28,

48 This presentation contains certain statements that may be deemed forward-looking statements. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by Solvay s and/or Rhodia's management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation are also subject to a number of risks and uncertainties resulting from numerous factors, including economical, political and technological factors that may affect the operations of Solvay and Rhodia, their markets, products, services and prices. Such forward-looking statements are not guarantees of future performance, and actual results and developments may differ from those envisaged by such forward-looking statements. This presentation does not constitute and cannot be construed as an Offer or invitation to purchase any securities of Rhodia by Solvay. The Offer when made will be made solely by means of the Offer document setting out the terms and conditions of the Offer. In accordance with French law, the Offer documents setting out the terms and conditions of the Offer will be subject to review by the French market authority (AMF). Shareholders and other investors are invited to read carefully all documents relating to the Offer prior to making any decision with respect to the Offer. 4848

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic

More information

Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Solvay expands its specialty polymers offerings with Ryton PPS acquisition Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty

More information

Solvay. Brigitte Laurent Senior Vice President Group Innovation Champion. SOLVAY S.A. Proprietary

Solvay. Brigitte Laurent Senior Vice President Group Innovation Champion. SOLVAY S.A. Proprietary Innovation @ Solvay Brigitte Laurent Senior Vice President Group Innovation Champion May 18th, 2011 Outline Solvay Group Innovation highlights : Key initiatives Conclusions 2011, SOLVAY SA 2 About Us SOLVAY

More information

Passion for progress, care for people

Passion for progress, care for people Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.

More information

GBU data & processes

GBU data & processes GBU data & processes Consumer Chemicals Novecare at a Glance Growth on inspired products Net sales 2013e 1.6 bn 11 prod. Sites (+1 under construction) 12 R&I centers 5 prod. Sites (+1 under construction)

More information

Global Polybutylene Terephthalate (PBT) Market Study ( )

Global Polybutylene Terephthalate (PBT) Market Study ( ) Global Polybutylene Terephthalate (PBT) Market Study (2014 2025) Table of Contents 1. INTRODUCTION 1.1. Introduction to Polybutylene Terephthalate Market Product Description Properties Industry Structure

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Global Terephthalic Acid (PTA) Market Study ( )

Global Terephthalic Acid (PTA) Market Study ( ) Global Terephthalic Acid (PTA) Market Study (2014 2025) Table of Contents 1. INTRODUCTION 1.1. Introduction to Terephthalic Acid Market Product Description Properties Industry Structure Value Chain Market

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria

Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria FINANCIAL TIMES INVESTING IN BULGARIA CONFERENCE Investment Opportunities in Bulgaria The Case of Solvay Sodi Spiros Nomikos CEO of Solvay Sodi

More information

The acquisition of Fortitech

The acquisition of Fortitech The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

Solvay India April 2017

Solvay India April 2017 Solvay India April 2017 Solvay in India Ahmedabad, Jodhpur, Bhiwani Hichem (JV) (GUAR) Solvay Specialty Polymer India & Panoli Solvay Engineering Plastics (PEEK, PAEK Polysulfones, Polyamide compounds)

More information

Endesa 1Q 2017 Results 09/05/2017

Endesa 1Q 2017 Results 09/05/2017 Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7

Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7 Solvay Media Kit Table of Contents 1. About Solvay 3 1.1. Solvay at a Glance 4 1.2. Group Portfolio 5 2. Transforming Solvay 6 2.1. Solvay s Portfolio Upgrade 7 3. Organizing for the Future 9 3.1. Why

More information

DELICA D:5 ACTIVE GEAR 0

DELICA D:5 ACTIVE GEAR 0 DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion

More information

Global Zinc Chemicals Market Study ( )

Global Zinc Chemicals Market Study ( ) Global Zinc Chemicals Market Study (2014 2025) Table of Contents 1. INTRODUCTION 1.1. Introduction to Zinc Chemicals Market Product Description Properties Industry Structure Value Chain Market Dynamics

More information

1Q2005. Hera Group presentation

1Q2005. Hera Group presentation 1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

ELICA 2012 Q3 RESULTS. November 14,

ELICA 2012 Q3 RESULTS. November 14, ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation

More information

For personal use only

For personal use only Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for

More information

Building a model of sustainable chemistry

Building a model of sustainable chemistry Building a model of sustainable chemistry March, 2015 Focused on bringing worldclass & sustainable Chemistry Solvay in India 264 million net sales ( Excl. JV but includes ~64 meuro export) 778 Employees

More information

Very good Q3 contribution from Vegetable Juices Inc.

Very good Q3 contribution from Vegetable Juices Inc. 2014 nine-month sales (1 st January to 30 September 2014) Very good Q3 contribution from Vegetable Juices Inc. Worldwide economic environment still adverse Sustained growth by Food & Beverage Press release

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

Driving Profitable Growth

Driving Profitable Growth Driving Profitable Growth through science-based, sustainable solutions Feike Sijbesma, CEO Royal DSM CONSUMER ANALYST GROUP EUROPE, London 22 March 2016 ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor

More information

BALCHEM CORPORATION. Q Investor Relations Presentation

BALCHEM CORPORATION. Q Investor Relations Presentation BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life

More information

1Q 2015 Results A Positive Start to 2015

1Q 2015 Results A Positive Start to 2015 1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

Südzucker Group Capital market forum Rhine Neckar

Südzucker Group Capital market forum Rhine Neckar Südzucker Group Capital market forum Rhine Neckar Mannheim, 7 November 2017 Thomas Kölbl (CFO) Südzucker Group, page 1 Südzucker Group at a glance Global operating German food group with long-standing

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation June 2012 NASDAQ: CEMI Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act

More information

GROWTH NOW! Franck Riboud

GROWTH NOW! Franck Riboud GROWTH NOW! Franck Riboud June 15 h, 2010 Disclaimer This document contains certain forward-looking statements concerning DANONE. Although DANONE believes its expectations are based on reasonable assumptions,

More information

Investor Presentation

Investor Presentation Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

DuPont Nutrition & Health Craig Binetti, President

DuPont Nutrition & Health Craig Binetti, President Craig Binetti, President Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m.

MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m. MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m. The shareholders of the company Solvay S.A. with its corporate offices in Brussels, rue de Ransbeek, no. 310,

More information

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to

More information

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Letter to Shareholders SEMI-ANNUAL REPORT 2008 Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

A GLOBAL LEADER IN PERSONALIZED NUTRITION

A GLOBAL LEADER IN PERSONALIZED NUTRITION A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

Environmental, Health and Safety

Environmental, Health and Safety Environmental, Health and Safety Codes of Practice The Environmental, Health and Safety (EHS) Codes of Practice set forth Zimmer EHS requirements for our business functions and facilities worldwide. In

More information

Nomura Healthcare Conference

Nomura Healthcare Conference Nomura Healthcare Conference Sebastien Martel Head of Investor Relations London, July 1st, 2011 Forward Looking Statements 2 This presentation contains forward-looking statements as defined in the Private

More information

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)

More information

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

An exciting combination in a high growth, high margin Nutrition category. Name of chairman An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

Launch of a new binders : Leveraging innovation to an economic advantage.

Launch of a new binders : Leveraging innovation to an economic advantage. Launch of a new binders : Leveraging innovation to an economic advantage. Maximizing customers benefit by reducing cost of change Roberta Colombo & Thierry Baert The cost of innovation for materials. The

More information

MARCH 2014 RESULTS PRESENTATION Madrid, 2014

MARCH 2014 RESULTS PRESENTATION Madrid, 2014 MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted

More information

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1 Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking

More information

PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION

PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition

More information

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth

More information

Results Briefing. 15 ~ 17 May 2007

Results Briefing. 15 ~ 17 May 2007 Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company

More information

Consolidated: Financial Summary

Consolidated: Financial Summary FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

WELCOME TO ACTELION S AGM 2015

WELCOME TO ACTELION S AGM 2015 WELCOME TO ACTELION S AGM 2015 08 May 2015 Copyright 2015 Actelion Pharmaceuticals Ltd ACTELION S ANNUAL GENERAL MEETING 2015 MEETING STRUCTURE Opening Remarks Business Review 2014 Agenda & Proposals Jean-Pierre

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

GELATIN & AKIOLIS. Because every bio-molecule counts. Pol Deturck EVP Chemicals & Organic Specialties

GELATIN & AKIOLIS. Because every bio-molecule counts. Pol Deturck EVP Chemicals & Organic Specialties GELATIN & AKIOLIS Because every bio-molecule counts Pol Deturck EVP Chemicals & Organic Specialties Why our bioplatform is promising Dual service provider and highly reliable partner Akiolis, the 3 rd

More information

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of

More information

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011 Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee

More information

Health for Humanity 2020 Goals 2

Health for Humanity 2020 Goals 2 2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus

More information

Leading Intimate Healthcare. Investor presentation Q1 2007/08

Leading Intimate Healthcare. Investor presentation Q1 2007/08 Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1

More information

Financial Presentation

Financial Presentation Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with

More information

PROCESS ECONOMICS PROGRAM

PROCESS ECONOMICS PROGRAM PROCESS ECONOMICS PROGRAM SRI INTERNATIONAL Menlo Park, California 94025 Process Economics Program Report No. 61C CHLORINR (December 1982) Abstract In this report SRI comprehensively reviews the technology

More information

Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022

Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022 Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022 By Value (In Million USD) By Volume (In Million Units)

More information

Putting ALK on the right growth trajectory

Putting ALK on the right growth trajectory Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large

More information

Solvay group «Profitable & Sustainable Growth: strategy and execution»

Solvay group «Profitable & Sustainable Growth: strategy and execution» Solvay group «Profitable & Sustainable Growth: strategy and execution» November 2007 MOVING FORWARD TOGETHER Table of contents PROFITABLE & SUSTAINABLE GROWTH: strategy and execution FURTHER GROWTH OUTLOOK

More information

Silica Fume Market by Application (Building Construction, Marine Structure Construction, Oil & Gas Well Grouting, Nuclear Power Plant Construction,

Silica Fume Market by Application (Building Construction, Marine Structure Construction, Oil & Gas Well Grouting, Nuclear Power Plant Construction, Silica Fume Market by Application (Building Construction, Marine Structure Construction, Oil & Gas Well Grouting, Nuclear Power Plant Construction, Chemical Production Facilities Construction, by Geography

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s

More information

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15. [NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS

More information

Country Coverage. Company Coverage

Country Coverage. Company Coverage Global Heart Valve Devices Market: Analysis By Procedure (Replacement & Repair), Replacement Procedure By Technique (Mechanical, Bioprosthetic & TAVR), Repair Procedure By Technique (Surgical, Balloon

More information

Third-quarter results 2013

Third-quarter results 2013 Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen

More information

Corporate Presentation October New growth cycle and value innovation

Corporate Presentation October New growth cycle and value innovation Corporate Presentation October 2017 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational

More information

More information at

More information at Report Information More information at https://www.htfmarketreport.com/reports/1288313 Global Homeopathic Products Market Professional Survey Report 2018 Report Code: HTF1288313 Pages: 111 Price: 1-User

More information

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars

More information

1Q 2014 Earnings Release

1Q 2014 Earnings Release 1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains

More information

Food Specialties Patrick Niels President DSM Food Specialties ROYAL DSM HEALTH NUTRITION MATERIALS

Food Specialties Patrick Niels President DSM Food Specialties ROYAL DSM HEALTH NUTRITION MATERIALS Food Specialties Patrick Niels President DSM Food Specialties ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s future

More information

Distribution Partner Briefing: A Partnership for Profit. Welcome to Smartcool s information package for prospective channel partners.

Distribution Partner Briefing: A Partnership for Profit. Welcome to Smartcool s information package for prospective channel partners. Distribution Partner Briefing: A Partnership for Profit Welcome to Smartcool s information package for prospective channel partners. This publication is intended only as a general guide to assist you in

More information

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( )

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( ) Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,

More information